More Drug Pricing Probes: Merck, Lilly Targeted
This article was originally published in Scrip
Executive Summary
Merck & Co. and Eli Lilly and Co. are the latest drug makers to reveal their pricing practices have caught the attention of federal prosecutors – both disclosing in recent Securities and Exchange Commission (SEC) filings the US Attorney's Office for the Eastern District of Pennsylvania has got the companies in its sights.